Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reata Expands Options For Bardoxolone With New CKD Data

Executive Summary

Once suspended due to safety issues, bardoxolone now has completed a Phase II study that showed kidney function benefit in four rare types of CKD. A pivotal study is underway, with another planned and more possible.

You may also be interested in...



Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration

GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.

Pay Day For Reata As Bardoxolone Progresses For Kidney Disease In Japan

Reata reaps benefit from 2009 licensing deal with Kyowa Hakko Kirin for bardoxolone as transcription factor activator moves into pivotal study for kidney disease in Japan.

Outlook For Reata's Bardoxolone Improves With Phase II Updates

Latest data support moving bardoxolone into Phase III for autosomal dominant polycystic kidney disease (ADPKD).

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC124703

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel